Table 1 Baseline demographics, diseases, treatments, side effects, blood values and infection parameters of 20 patients in reviewed case reports (y = years, ICI = Immune Checkpoint Inhibitor, irAE = Immune-related side effects, n.a. = not applicable)
Patient | Age (y) | Cancer disease | ICI | irAE (besides neutropenia) | Neutrophil count (G/l) | Hemoglobin values (g/l) | Thrombocyte count (G/l) | Reported strain | Fever | Antibiotic therapy |
|---|---|---|---|---|---|---|---|---|---|---|
1 | 42 | Melanoma | Ipilimumab | Rush | 0.3 | 108 | 202 | None | Yes | Yes |
2 | 74 | Melanoma | Ipilimumab | Not documented | 0 | 62 | 158 | None | Yes | Yes |
3 | 77 | Melanoma | Ipilimumab | Endocrine | 0 | 88 | 71 | R. plantocola and E. cloacae | Yes | Yes |
4 | 49 | Melanoma | Ipilimumab | None | 0 | Normal | Normal | None | Yes | Yes |
5 | 70 | Melanoma | Ipilimumab | Rush | 0.3 | 70 | n.a. | None | No | n.a. |
6 | 35 | Melanoma | Ipilimumab | None | 0 | 76 | 256 | None | Yes | Yes |
3 | 54 | Melanoma | Ipilimumab | Rush, endocrine | 0 | n.a. | 127 | None | Yes | Yes |
8 | 74 | Lung cancer (adenocarcinoma) | Nivolumab | Rush, hepatitis | 0 | n.a. | n.a. | S. aureus | No | Yes |
9 | 48 | Melanoma | Nivolumab and ipilimumab | None | 0 | 115 | < 5 | None | Yes | Yes |
10 | 38 | Primary mediastinal B-cell lymphoma | Nivolumab | None | 0 | n.a. | n.a. | None | n.a. | n.a. |
11 | 73 | Lung cancer (adenocarcinoma) | Nivolumab | Colitis | 0 | n.a. | n.a. | None | Yes | Yes |
12 | 74 | Lung cancer (adenocarcinoma) | Nivolumab | None | 0 | 119 | 249 | None | n.a. | n.a. |
13 | 57 | Glioblastom | Nivolumab | Rush | 0 | 68 | 5 | Moxarella catarrhalis | Yes | Yes |
14 | 51 | Melanoma | Nivolumab and ipilimumab | Endocrine | 0 | 77 | 346 | None | n.a. | n.a. |
15 | 56 | Lunge cancer (adenocarcoma) | Nivolumab | None | 0.1 | 100 | 40 | Fusarium solani | Yes | Yes |
16 | 59 | Melanoma | Nivolumab and ipilimumab | Rush, hepatitis, colitis | 0.3 | n.a. | n.a. | None | n.a. | n.a. |
17 | 73 | Lung cancer (adenocarcinoma) | Pembrolizumab | Not documented | 0 | n.a. | n.a. | None | Yes | Yes |
18 | 82 | Lung cancer (pleomorphic carcinoma) | Pembrolizumab | Pneumonitis | 0.1 | Normal | Normal | None | Yes | Yes |
19 | 65 | Melanoma | Nivolumab and ipilimumab | Colitis | 0 | 103 | 227 | None | Yes | Yes |
20 | 56 | Melanoma | Nivolumab and anti-LAG-3 | None | 0 | 144 | 288 | None | Yes | Yes |